Cellectar Biosciences (CLRB) EBITDA Yield: History & Chart

Cellectar Biosciences, Inc.(CLRB)

Biotechnology · Florham Park, NJ

$1.66-0.01 (-0.60%)

Delayed quote: Oct 6, 2026, 10:04 AM EDT

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

Florham Park, NJ

11 employees

www.cellectar.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: James V. Caruso

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Cellectar Biosciences, Inc. (CLRB)	$13.26M	N/A	N/A	N/A	N/A
Vyome Holdings, Inc. (HIND)vs ›	$13.48M	N/A	N/A	N/A	N/A
Dare Bioscience, Inc. (DARE)vs ›	$12.74M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.91M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.14M	N/A	0.87%	0.87%	0.87%
IRIDEX Corporation (IRIX)vs ›	$12.12M	N/A	0.96%	2.71%	3.80%
Lantern Pharma Inc. (LTRN)vs ›	$11.83M	N/A	N/A	N/A	N/A
Cytosorbents Corporation (CTSO)vs ›	$11.81M	N/A	N/A	N/A	N/A
Adial Pharmaceuticals, Inc. (ADIL)vs ›	$11.50M	N/A	N/A	N/A	N/A
Lisata Therapeutics, Inc. (LSTA)vs ›	$11.47M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Cellectar Biosciences, Inc. (CLRB)

$13.26M

N/A

Vyome Holdings, Inc. (HIND)vs ›

$13.48M

N/A

Dare Bioscience, Inc. (DARE)vs ›

$12.74M

N/A

IN8bio, Inc. (INAB)vs ›

$13.91M

N/A

Citius Pharmaceuticals, Inc. (CTXR)vs ›

$14.14M

N/A

0.87%

IRIDEX Corporation (IRIX)vs ›

$12.12M

N/A

0.96%

2.71%

3.80%

Lantern Pharma Inc. (LTRN)vs ›

$11.83M

N/A

Cytosorbents Corporation (CTSO)vs ›

$11.81M

N/A

Adial Pharmaceuticals, Inc. (ADIL)vs ›

$11.50M

N/A

Lisata Therapeutics, Inc. (LSTA)vs ›

$11.47M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

CLRB EBITDA Yield Metrics

CLRB Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics